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Abstract
To assess the diagnostic accuracy of CA125, its kinetic values and positron emission tomography/computed tomography with 2-
deoxy-2-[18F]fluoro-D-glucose ([18F]FDG-PET/CT), in relation with tumor characteristics for suspected recurrence of ovarian cancer.
To evaluate the performance of CA125-related parameters as a selection criteria to perform a [18F]FDG-PET/CT.
A retrospective analysis of 69 [18F]FDG-PET/CT for suspected recurrence of ovarian cancer was performed. All patients had 2
measurements of CA125, before PET/CT, to calculate kinetic values, as CA125vel (CA125vel = [CA125a  CA125b]/time) and
CA125dt (CA125dt= [log2 time]/[logCA125aCA125b]).Maximumstandarduptake value (SUVmax)wascalculated.Thediagnostic
accuracywas calculated for all the variables and the optimal cut-off value of eachof themby the receiver-operating characteristics (ROC)
analysis. All the tests were comparedwith tumor characteristics and clinical-radiological evolution during follow-up of at least 6months.
Fifty-fivecaseswerediagnosedof recurrence (11withCA125<35U/mL),while 14showednodisease (11withCA125<35U/mL).All
of themwere correctly cataloged byPET/CT.CA125, CA125vel, andSUVmax showed higher levels in recurrent patients (mean 129.54
U/mL, 24.58U/mL per mo, and 8.69g/mL, respectively) than in nonrecurrent (mean 20.35U/mL, 0.60U/mL per mo, and 0.64g/mL,
respectively). No statistical differences in CA125dt were found. Patients with recurrence of high-grade serous carcinoma (HGSC)
showed higher CA125 and CA125vel, without differences in the rest of subtypes and International Federation of Gynecology and
Obstetrics stages. The ROC analyses for CA125, CA125vel, and CA125dt showed an area under the curve (AUC) of 0.873 (95%
confidence interval [CI] 0.77–0.969), 0.903 (95%CI0.813–0.994), and0.727 (95%CI0.542–0.913), respectively,with anoptimal cut-off
point of 23.95U/mL, 4.49U/mL per mo, and 3.36 months, respectively, while for the SUVmax the AUC was of 0.982 (95% CI 0.948–
1.000), and the cut-off point of 2. Multivariate regression analysis identified CA125 and CA125vel as predictors of recurrence.
[18F]FDG-PET/CT ismore accurate than the parameters obtained from the CA125 to detect early recurrence. CA125vel is themost
suitable parameter, mainly in HGSC. Levels of CA125vel ≥ 4.49U/mL per mo facilitate earlier detection by the execution of a [18F]
FDG-PET/CT. The calculation of these parameters is independent of tumor stage at diagnosis.
Abbreviations: [18F]FDG= 2-deoxy-2-[18F]fluoro-D-glucose, 95%CI= 95%confidence interval, AUC= area under the curve, CA125
= cancer antigen 125, CA125dt = CA125 doubling time, CA125vel = CA125 velocity, CCC = clear cell carcinoma, EC = endometrioid
carcinoma, EOC = epithelial ovarian cancer, FIGO = International Federation of Gynecology and Obstetrics, HGSC = high-grade serous
carcinoma, LGSC = low-grade serous carcinoma, MC = mucinous carcinoma, PET/CT = positron emission tomography/computed
tomography, ROC = receiver-operating characteristics, SD = standard deviation, SUVmax = maximum standard uptake value.
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Epithelial ovarian cancer (EOC) is a heterogeneous disease.
Nowadays, it is widely recognized that the histological subtypes
constitute 5 different diseases: low-grade serous carcinoma
(LGSC), high-grade serous carcinoma (HGSC), endometrioid
carcinoma (EC), mucinous carcinoma (MC), and clear cell
carcinoma (CCC). EOC continues being the main cause of death
from gynecologic malignancies, although the 5-year survival rate
has increased in last decade.[1] The poor survival rate is attributed
to frequent persistence or recurrence of disease. However,
recurrence varies from 10% for stage I to 85% for stage IV with
suboptimal debulking.[2]
The cancer antigen 125 (CA125) has an established role as a
serum tumor marker, and it has been routinely used for
monitoring ovarian cancer patients. Regular measurements
during follow-up can detect recurrence of cancer months before
symptoms or alterations in the conventional imaging techni-
ques.[3,4] However, CA125 originates from the mesothelial cells
Palomar Muñoz et al. Medicine (2018) 97:17 Medicineof the coelomic epithelium, so it rises in related pathologies,
leading to poor sensitivity and specificity of a single determina-
tion. Therefore, an elevated CA125 is not always indicative of
recurrence and there is no evidence of a survival benefit with early
treatment of relapse based on a raised CA125 concentration
alone.[5] This forces to discriminate between relapse of ovarian
cancer and benign increases. On contrary, a rise of CA125 could
mean recurrence, even in cases of serum levels below the range of
normality, so that doubling in CA125 from the upper limit of
normal means objective progression.[4] In fact, the pattern of
serum CA125 level ascent, gradual or abrupt, in patients in
complete remission has prognostic value.[5] This suggest that if
changes in CA125 are assessed in isolation, but considering
variations that occur over the time, recurrence could be detected
earlier.[6]
Based on the fact that positron emission tomography/
computed tomography with 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG-PET/CT) could detect ovarian recurrences, even with
low titles of CA125,[7–9] the aim of our work was to assess the
accuracy of both techniques, as well as CA125 kinetic values,
expressed as CA125 velocity (CA125vel) and CA125 doubling
time (CA125dt), and their relation with tumor characteristics at
the time of diagnosis. And also, to select the best time to perform a
[18F]FDG-PET/CT that allows an early detection of recurrent
ovarian cancer.2. Materials and methods
We retrospectively enrolled consecutive patients with suspicion
of EOC recurrence, during the period of 2007 to 2015, referred to
our center in order to perform a [18F]FDG-PET/CT. This study
was performed with institutional review board approval (Ethical
Committee for Clinical Research, Hospital General Universitario
de Ciudad Real), and informed written consent was obtained
from each patient. All patients had been treated for ovarian
cancer according to the extension of the disease, achieving a
complete remission after the treatment for at least 6 months.
Patients were classified by the histological subtypes of EOC at
diagnosis, HGSC, LGSC, EC, MC, and CCC. Likewise, the
International Federation of Gynecology and Obstetrics (FIGO)
stage at diagnosis was considered[10] and was divided into early
or advanced stages that involve stages I and II, and III and IV,
respectively.
The suspicion of recurrence was based on elevation of CA125
serum levels, alterations in the conventional imaging techniques
(CT or magnetic resonance imaging) and/or by the appearance of
symptoms. Inclusion criteria also include CA125 elevation at
diagnosis of disease and measurement of CA125 in 2 consecutive
occasions, to calculate the kinetic values. Patients referred twice
to our center, with a time difference exceeding 6 months, that
meet the inclusion criteria were included in the analysis in both
cases. Platinum-resistant patients (the tumor recurs <6 months
after completing chemotherapy) or platinum-refractory (the
tumor progresses during the adjuvant chemotherapy), and
patients referred to assess response to treatment or suspected
progression, were excluded.
The kinetic values of CA125 were evaluated, using 2
consecutive measurements. CA125vel was calculated by the
following formula: (CA125aCA125b)/Time, where CA125a is
the CA125 serum level closest to the PET/CT scan, measured at
most 1 month around, CA125b is the immediately previous to
CA125a, and Time is the time between these 2 measurements,
expressed in months. CA125dt was calculated by natural log of 22
(0.693) divided by the slope of the relationship between the log of
CA125 and time of CA125 measurement for each patient. The
CA125 cut-off value for recurrence is fixed at 35U/mL.
A hybrid PET/CT scanner was used to obtain images 60min
after administration of 370 MBq of [18F]FDG, from the orbital-
metal line to the proximal third of the lower limbs. First, low-dose
CT images were acquired (120kV, 80mA), followed by PET in
3D mode with an acquisition time of 3min per bed. The [18F]
FDG-PET/CT images were revised by 2 experienced nuclear
medicine physicians, unaware of the clinical data, and the
diagnosis was reached by consensus. They were classified as
normal if there was no uptake outside expected physiological
locations. All the areas presenting an increased tracer uptake
above the background, not concordant in the CT images with
areas of physiological activity or changes suggestive of infectious
or inflammatory processes, were considered positive, and
therefore compatible with relapse. The lesion with higher activity
was measured by maximum standard uptake value (SUVmax). In
those cases of normal [18F]FDG-PET/CT, SUVmax was consid-
ered 0.
The final diagnosis of recurrence was made by histological
confirmation or clinical-radiological follow-up longer than 6
months, further increase in tumor marker levels without
treatment, clinical worsening of the patients’ condition, or a
response to therapy in the conventional imaging techniques.
Instead, nonrecurrence cases were finally cataloged if there was
no progression within 6 months in absence of treatment or if
histological analysis confirmed the benign nature of the lesions.
Statistical analysis of data was carried out using IBM SPSS
Statistics v. 19.0 (IBM Corp., Armonk, NY). Normally
distributed continuous variables were compared using t test
for independent samples. The analysis of variance test was used
for defining the difference among subsets of patients, in relation
to histological subtypes and stages, early or advanced, at
diagnosis. The receiver-operating characteristics (ROC) curve
was generated and assessed to find the best cut-off point for
CA125, CA125vel, and CA125dt to predict recurrence detected
by [18F]FDG-PET/CT. A multivariate analysis was used to
identify variables associated with recurrent disease. Values of
P< .05 were considered statistically significant.3. Results
During the studied period, we performed 69 [18F]FDG-PET/CT
scans in 58 patients [mean (standard deviation [SD]) age 59.96
(12.6) years] with suspicion of recurrent EOC, who meet the
inclusion criteria. Patients and tumor characteristics are shown in
Table 1.
From these, 55 studies of 45 patients showed pathological [18F]
FDG uptake and were finally diagnosed of ovarian cancer
recurrence. Among them, in 20 patients (5 of them twice),
recurrence was verified after surgery or histological analysis,
while the remaining 30 cases were diagnosed by clinical and
radiological follow-up (mean 28.42 months, SD 19.50). In 14
cases, a normal distribution of [18F]FDG was observed,
categorizing them as nonrecurrence, which was confirmed in
the clinical and radiological follow-up. All cases histologically
confirmed showed tumor disease, without false negative results.
Although in 9 cases, considered as true positive, there was a
combination of tumor and inflammatory pathology. At follow-
up, all patients with active treatment presented progression (9
cases) or response to chemotherapy administered (21 cases). On
the other hand, in the follow-up of untreated patients, no disease
Table 1
Clinical characteristics.
Characteristics Patients, n (%) PET/CT, n (%)
Patients
Menopausal 44 (75.9) 53 (76.8)
Nonmenopausal 14 (24.1) 16 (23.2)
Histological type
High-grade serous 35 (60.4) 45 (65.2)
Low-grade serous 4 (6.9) 4 (5.8)
Endometrioid 12 (20.7) 13 (18.8)
Mucinous 5 (8.6) 5 (7.3)
Clear cells 2 (3.4) 2 (2.9)
FIGO stage at diagnosis
I 15 (25.9) 15 (21.7)
II 5 (8.6) 5 (7.3)
III 34 (58.6) 45 (65.2)
IV 4 (6.9) 4 (5.8)
FIGO= International Federation of Gynecology and Obstetrics, PET/CT=positron emission
tomography/computed tomography.
Table 2
Diagnostic accuracy per patient of CA125 serum levels and visual
[18F]FDG-PET/CT for recurrence ovarian cancer.
CA125 PET/CT
Sensitivity, % (95% CI) 80 (66.63–89.13) 100 (99.87–99.83)
Specificity, % (95% CI) 78.57 (48.82–94.29) 100 (73.24–99.34)
Positive predictive value, % (95% CI) 93.62 (81.44–98.34) 100 (91.87–99.83)
Negative predictive value, % (95% CI) 50 (28.80–71.20) 100 (73.24–99.34)
Accuracy, % (95% CI) 79.71 (67.98–88.08) 100 (93.43–99.87)
[18F]FDG = 2-deoxy-2-[18F]fluoro-D-glucose, 95% CI = 95% confidence interval, CA125=cancer
antigen 125, PET/CT=positron emission tomography/computed tomography.
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entails a sensitivity and specificity of 100% for PET/CT.
Among the cases with CA125 serum level below the normal
limit (35U/mL), 11 out of 22 (50%) were finally diagnosed with
recurrence, while from the 47 cases of CA125 > 35U/mL
recurrence was detected in 44. This results in a sensitivity of 80%
(66.63–89.13%), a specificity of 78.57% (48.82–94.29%), andFigure 1. Mean of cancer antigen 125 (CA125), kinetic values of CA125 (CA125ve
histological subtypes, in recurrence and in nonrecurrence cases.
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an accuracy of 79.71% (67.98–88.08%). Table 2 shows the
diagnostic accuracy for both tests.
The recurrent group showed higher levels than the nonrecur-
rent 1 for SUVmax (mean 8.69, SD 3.64 vs. 0.64, SD 1.67,
P< .001), CA125 (mean 129.54, SD 169.48 vs. 20.5, SD 22.14,
P< .001), and CA125vel (mean 24.58, SD 45.40 vs. 0.60, SD
3.34, P< .001), while the CA125dt had not shown statistical
differences (mean 2.16, SD 27.41 vs.17.25, SD 43.67, P= .13).
There was not statistical significance in the relation between the
histological subtypes, attending to CA125 (P= .49), its kinetic
values (CA125vel, P= .49; CA125dt, P= .87), or SUVmax
(P= .53). We subdivided each histological subtype in recurrence
and nonrecurrence group (Fig. 1). There were no differences in
relation to the CA125dt. Statistical significance was onlyl and CA125dt), and maximum standard uptake value (SUVmax) regarding the
Figure 2. Comparison of the cancer antigen 125 (CA125), kinetic values of CA125 (CA125vel and CA125dt), and maximum standard uptake value (SUVmax) in
different tumor stages (early [n=20] and advance [n=49]) at the time of diagnosis.
Figure 3. The ROC analysis demonstrated an optimal cut-off value for cancer
antigen 125 (CA125) serum level of 23.95U/mL, for the CA125dt of 3.365
months and for the CA125vel of 4.49U/mL per mo. The AUCs for CA125,
CA125dt, and CA125vel were, respectively, of 0.873, 0.727, and, 0.903. For
the SUVmax the optimal cut-off was 2, with an AUC of 0.982. AUC = area
under the curve, ROC = receiver-operating characteristics.
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SUVmax, and in the LGSC and the EC for the SUVmax.
In relation to the stage at diagnosis, early or advanced, there
were no statistical differences between levels of CA125 (P= .54),
CA125vel (P= .27), CA125dt (P= .77), and SUVmax (P= .96).
However, when we compared recurrent and nonrecurrent
disease, we found significant differences in the early stages in
SUVmax, CA125, and CA125dt, and in the advanced stages in
SUVmax, CA125, and CA125vel. There were no differences
neither in the CA125vel in early and the advanced stages nor in
the CA125dt. These results can be seen in Fig. 2.
The ROC analysis (Fig. 3) demonstrated an optimal cut-off
value for CA125 of 23.95U/mL, achieving a sensitivity of 87.3%
and a specificity of 78.6%, with an area under the curve (AUC) of
0.873 (95% confidence interval [CI] 0.777–0.969, P< .001) in
the prediction of recurrence. About the aim of the kinetic values
of CA125 in detecting recurrence we observed, an optimal cut-off
for the CA125dt of 3.36 months (sensibility 58.2%, specificity
71.4%) with an AUC of 0.727 (95% CI 0.542–0.913, P< .01).
On the other hand, the analysis revealed a cut-off for the
CA125vel of 4.49U/mL per mo (sensibility of 63.6%, specificity
of 92.9%), with an AUC of 0.903 (95% CI 0.813–0.994,
P< .001). For the SUVmax an optimal value of 2 was observed,
with a sensitivity of 98.2% and a specificity of 92.9%. The AUC
for it was 0.982 (95% CI 0.948–1.000, P< .001).
The results obtained by multivariate cox regression are shown
in Table 3.4
Table 3
Multivariate cox regression analysis.
Variables HR 95% CI P
Age 1.065 1.010–1.124 .021
Menopausal status 0.080 0.014–0.455 .004
Histology
HGSC 0.280 0.030–2.643 .267
LGSC 0.142 0.009–2.277 .168
EC 0.498 0.053–4.637 .540
MC 1.416 0.148–13.511 .763
CCC Reference .107
Stage 0.468 0.216–1.012 .054
SUVmax 1.052 0.971–1.141 .213
CA125 0.992 0.987–0.998 .010
CA125vel 1.035 1.012–1.059 .003
CA125dt 0.993 0.983–1.003 .164
95% CI = 95% confidence interval, CA125 = cancer antigen 125, CA125dt = CA125 doubling time,
CA125vel= CA125 velocity, CCC= clear cell cancer, EC= endometrioid cancer, HGSC= high-grade
serous carcinoma, HR = hazard ratio, LGSC = low-grade serous carcinoma, MC = mucinous cancer,
SUVmax = maximum standard uptake value.
Palomar Muñoz et al. Medicine (2018) 97:17 www.md-journal.com4. Discussion
An adequate follow-up is necessary in the ovarian cancer, to detect
and treat the recurrence as early as possible. If CA125 is used in
isolation we could detect the recurrent disease too late, in patients
with lower levels than the reference limit, or even we could treat
patients with elevated CA125, due to nontumor causes. So, efforts
are now directed to improve the accuracy of the measurements to
upgrade the precision in the early detection of recurrence. EOC
subtypes have been demonstrated that are inherently different
diseases. Regarding CA125 serum levels, HGSC and LGSC
showedhigher concentrations, followedbyECandCCC,while it is
less frequent in MC.[11,12] Our work, despite the distribution of
histologies resembles that seen all over inovarian cancer,[1] showed
greater CA125 serum levels inHSGC and EC, and lower in LGSC,
MC, and CCC, without statistical differences between recurrent
and nonrecurrent cases, except in HGSC.
Some authors[4] have recommended that patients must show
evidence of CA125 ≥ 2 times the upper limit of the reference
range or nadir value on 2 occasions, at least 1 week apart, to be
considered in recurrence. In our series, CA125 nadir has not been
considered, and that could be a selection bias, but all patients had
2 measurements of CA125 that allowed to calculate kinetic
parameters. These parameters, as used in the initial assessment of
ovarian cancer,[13,14] may be of utility in assessing recurrence.
Thus, beyond the estimation of kinetic values of CA125, helps in
the selection of patients referred to perform a [18F]FDG-PET/CT
to detect early disease. In accordance with our findings,
CA125vel is the most useful parameter, due to the high AUC
showed in the ROC analysis. This is consistent with that
described in the work of Levy et al[5] in which 52 patients were
assessed by CA125 elevation above the normal limit. It was
evident that patients with a pattern of abrupt rise of CA125 had
worse prognosis than patients with a progressive increase.
In our sample, a mean of 24.58U/mL per mo was observed in
the recurrence group, higher than the observed in the non-
recurrence group (0.60U/mL per mo). Similarly, as previously
published in a work with 311 patients, using 25U/mL per mo as
the upper limit of grade of CA125 increase, could allow to
achieved a 100% specificity for detecting recurrence.[15] Global-
ly, the difference between CA125vel mean in recurrence and
nonrecurrence cases is 23.98U/mL per mo. This difference5
increases in case of HGSC, with a mean difference of 31.70U/mL
per mo between recurrent and nonrecurrent cases, while is lower
than 10U/mL per mo in the rest of histologies. Probably, this is
due to higher proliferation index that exhibits HGSC in
comparison with other histological subtypes.[1] The extension
of disease influences the proliferation of the tumor marker, that is
the reason why early stages usually exhibit median values for
CA125 lower than late stages.[11,12,16] But in our series, there are
no statistical differences between both groups, and neither in the
kinetic values. This could be due to the extension of the disease in
the recurrence (not analyzed in this paper), and not just the initial
spread of the disease.
As Prat et al previously published,[6] one of the early signs of
recurrence might be a low-level increase in CA125 serum values
within the normal range during surveillance for ovarian cancer
recurrence. That, as the ROC analysis demonstrated in our
sample, a rise of 4.49U/mL per mo should make us consider the
performance of PET/CT to rule out recurrence, without waiting
for a large increase of CA125. Even, the multivariate analysis
showed that CA125vel is the most influential factor in disease
detection. Thus, the calculation of CA125vel, which does not
take too long, because it is calculated by a simple formula, should
be determined in daily practice to improve recurrence detection,
even with very low levels of CA125.
On the other hand, the CA125dt, overall, has not shown
differences (P= .13) in patients with relapse and nonrecurrence,
with a mean difference of 19.41 months between them. The same
occurs in histological subtypes, with a nonstatistical difference in
any of the subgroup. The longitudinal CA125, which consists in
an analysis from diagnosis to completion of first-line chemother-
apy, has been proposed to predict recurrence. Because it showed
better predictive value than kinetic factors after the treatment, as
CA125 half-life, time to reach CA125 nadir and CA125 nadir.[17]
Moreover, the literature refers that patients with a doubling time
of CA125 shorter than 40 days have a significantly shorter
survival than those whose doubling time is >40 days (10.6
months vs. 22.1 months), independently of the time to disease
progression.[18] As a justification for our results, without
differences in recurrence and nonrecurrence groups, it is
important to note, as suggest Xu et al[13] that although the
doubling time is the same from 2 to 4U/mL and from 20 to 40U/
mL, the first offers a little indication of ovarian cancer recurrence,
whereas the second one in the same period provides a much
stronger indication. Which makes necessary to a better
assessment jointly assess CA125 serum level and doubling time,
achieve by the CA125vel.
According to our data, while CA125 serum levels have shown a
relatively low sensitivity and specificity, [18F]FDG-PET/CT has
correctly cataloged all cases, regardless of the level of CA125,
with a high prevalence of recurrence (79.71%). SUVmax showed
statistical differences between recurrent and nonrecurrent cases
in distinct histological subtypes. The exception was the mucinous
group, in which 1 patient showed an inflammatory activity
caused by mesenteric adenitis. That was correctly classified based
on the assessment of fusion, metabolic and anatomical images,
which are essential for a suitable categorizing of findings,
avoiding false positive results due to inflammatory processes.
SUVmax is influenced by glucose metabolism, and tumor
differentiation, proliferative potential, cell density, as well as
mucinous and fibrous components.[19] So mucinous tumors are
presupposed to have low [18F]FDG uptake, but metabolic rate of
tumor varies also depending on intratumoral heterogeneity.[20]
But the semiquantitative measurements should not be taken as
Figure 4. (A) Maximum intensity projection (MIP) and axial fusion positron emission tomography/computed tomography with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]
FDG-PET/CT) in a 68-year-old woman with recurrent ovarian cancer (FIGO stage IIIC, high-grade serous carcinoma, diagnosed 49 months before), with CA125 of
51.6U/mL, CA125vel of 4.6U/mL per mo and a doubling time of 7.4. Surgery confirmed the existence of a metastasis on right adrenal gland that showed high [18F]
FDG uptake (SUVmax 10.6). (B) Woman (70-year-old) with history of mucinous ovarian carcinoma, that showed rising CA125 (62.4U/mL), with a CA125vel of 5.4U/
mL per mo and CA125dt of 6.73. The [18F]FDG-PET/CT, MIP, and axial fusion PET/CT exhibited multiple lymph nodes in retroperitoneal space and both iliac
territories. All locations visualized in [18F]FDG-PET/CT, with an SUVmax of 7.3, were confirmed histologically. Both cases showed irregular intestinal uptake.
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in the ROC analysis, because it is not a “magic point” that can
differentiate malignant to benign lesions. Thus, the visual analysis
and, therefore, the diagnostic skill of nuclear medicine physicians
in the interpretation are essential. Beside the metabolic tumor
volume (MTV) and total lesion glycolysis (TLG) are parameters
that may help to individually tailor postoperative adjuvant
chemotherapy, better than SUVmax, because reflect the meta-
bolic burden and disease extent.[21]
The setting-up of the extent of the disease by PET/CT allowed
in 25 cases to perform surgery prior to the consolidation
chemotherapy (Fig. 4), while in 30 cases the chemotherapy was
administrated. The elevated levels of CA125 were not indicative
of tumor recurrence in 3 cases, and the PET/CT prevented
treatment administration. This, associated with the fact that
chemotherapy based on a raised CA125 concentration alone has
not demonstrated improved survival, suggests the need to assess
patients with suspected recurrent EOC by PET/CT. That is better
than a combination of conventional imaging techniques, to offer
site-specific therapy if possible. In the same way, Ebina et al[22]
demonstrated that [18F]FDG-PET/CT is a useful tool for selecting
candidates for cytoreductive surgery. They refer that patients
with localized [18F]FDG uptake patterns are the best candidates
for surgical therapy, and these patients usually have a treatment-
free interval of more than 6 months. The information of [18F]
FDG-PET/CT determines an improvement in restaging accuracy
and in the pathway cost. This is because [18F]FDG-PET/CT
reduces inappropriate surgical procedures with an impact on the
patients’ health and on the system expenses by distinguish a single
lesion, for which surgery is required, from multiple lesions, for
which surgery is not to be performed.[23]
The main limitations of our study are derived from its
nonrandomized retrospective nature and the small number of
patients, especially in the number of non-HGSC. In addition, they
were patients with a high prevalence of disease, due to the6
selection patients from PET/CT database. The inclusion criteria
could generate a selection bias, essentially, given the exclusion of
early recurrence. However, in our opinion, early recurrence is
mostly due to persistent undetectable disease despite treatment.
To minimize bias in the assessment of PET/CT nuclear medicine
physicians evaluated blindly. Further prospective studies would
be necessary to validate the current data, particularly in those
patients with early recurrence, considered platinum-resistant.5. Conclusions
[18F]FDG-PET/CT has proved to be more accurate than CA125
serum level to detect ovarian cancer recurrence allowing to
establish thus earlier the more adequate treatment. CA125vel is a
parameter easily calculated, that could better select those patients
that may benefit from the performance of a [18F]FDG-PET/CT
study. A CA125vel of 4.49U/mL per mo was observed as the
best cut-off; so, this variation could be employed to consider a
[18F]FDG-PET/CT, independently of CA125 serum levels.
The HGSC is the most beneficiary of this calculation, whereas
tumor stages present similar performance. Despite SUVmax
showed higher levels in recurrent disease, the multivariate
analysis showed that CA125 and CA125vel were independent
parameters in patients with recurrent EOC.
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